The news this week that there have been six reported cases of a rare and severe blood clot in women between the ages of 18 and 48 who have received the Johnson & Johnson vaccine is not the kind of news we welcome, but I am reassured, as I hope you are, that recommending a pause in the use of the vaccine was the right thing to do and helps show that we all take vaccine safety very seriously.
On Tuesday, the Department of Health and Welfare (DHW) issued a press release recommending that Idaho vaccine providers not use the Johnson & Johnson vaccine until more information is available from the Centers for Disease Control and Prevention (CDC). This recommendation was made after receiving information that the CDC and the Food and Drug Administration (FDA) also recommended a pause in the use of that vaccine and are reviewing the data for the six reported cases. All 50 states have made this same recommendation.
On Wednesday, April 14, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) met and did not put forth any formal recommendations during this meeting. Voting members are waiting for additional data for a more robust risk-benefit analysis, and that should be available to them next week. Additional discussion may address restrictions for vaccine use in highest risk populations, possibly by age or gender.
Although this is not news we were expecting, this is exactly what is supposed to happen with any new vaccine or drug or protocol: if there is an unexpected adverse reaction, there is a pause to review the data and then refine recommendations. The safety system in the United States works. The FDA and the CDC made the right decision to temporarily halt the use of this vaccine.Continue reading “An Update from DHW Director Dave Jeppesen: Johnson & Johnson Vaccine”